AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues and revenue growth. The report, which was prepared for the AHA, demonstrates that while the 340B program has grown, it remains a very small share of drug company revenues. At the same time, this growth has allowed 340B hospitals to provide more care to more patients just as Congress intended when it established the program over 30 years ago.

The report also describes the forces that have increased the scope of the 340B program, including legislation that expanded program eligibility to additional types of hospitals, such as critical access hospitals and other rural providers; policy decisions that have shifted care delivery from inpatient to outpatient settings; and changes to patent and extended exclusivity policies for drug companies. Other forces shaping the program include increases in the use of drugs, including both specialty drugs and medical advances that rely on drugs over other interventions, and sharply rising drug prices.

Related News Articles

Headline
The AHA May 1 expressed concerns (LINK) to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare…
Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation…
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from…
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model “was within its statutory…